Opinion statement
Dermatomyositis (DM) and polymyositis (PM) are idiopathic inflammatory myopathies characterized by proximal greater than distal muscle weakness, elevated serum creatine kinase levels, electrophysiologic abnormalities, and inflammation on muscle biopsy. Clinically and electrophysiologically, DM and PM appear very similar, and muscle biopsy is the gold standard for diagnosis. Much of the PM literature based the diagnosis on Bohan and Peter’s criteria, which is now obsolete given the advances of immunopathology. As diagnostic criteria for the inflammatory myopathies have been refined, it has become apparent that PM is much less common than previously thought, and, in fact, is probably quite rare. More recent literature, using strict histopathologic criteria for diagnosis of PM, has brought into question previously reported associations. Because of this, the clinical entity of PM is poorly defined. The exact incidence of each is unknown because previous epidemiologic studies often grouped them together, but overall the annual incidence of the inflammatory myopathies is approximately one in 100,000. DM and PM respond to immunomodulating therapies. High-dose oral prednisone is generally accepted first-line therapy. In patients who do not respond adequately to prednisone alone, or in whom prednisone cannot be weaned, methotrexate or azathioprine can be added. In the authors’ experience, methotrexate works faster and is more effective than azathioprine. However, because of the increased risk of interstitial lung disease with methotrexate, the authors avoid this in patients with anti-Jo-1 antibodies and, obviously, in patients who already have pulmonary disease. If patients do not respond adequately to the combination of prednisone and methotrexate or azathioprine, a trial of intravenous immunoglobulin is administered.
Similar content being viewed by others
References and Recommended Reading
Bohan A, Peters JB: Polymyositis and dermatomyositis: part 1. N Engl J Med 1975 292:344–347.
Bohan A, Peters JB: Polymyositis and dermatomyositis: part 2. N Engl J Med 1975, 292:403–407.
Dalakas MC: Polymyositis, dermatomyositis, and inclusion body myositis. N Engl J Med 1991, 325:1487–1498.
Dalakas MC: Progress in inflammatory myopathies: good but not good enough. J Neurol Neurosurg Psychiatry 2001, 70:569–573. This is a recent review that succinctly summarizes the current thinking regarding the clinical presentation, pathogenesis, and treatment of the idiopathic inflammatory myopathies.
Banker BQ, Victor M: Dermatomyositis (systemic angiopathy) of childhood. Medicine 1966, 45:261–289.
Cohen MG, Nash P, Webb J: Calcification is rare in adult-onset dermatopolymyositis. Clin Rheumatol 1986, 5:512–516.
Amato AA, Barohn RJ. Idiopathic inflammatory myopathies. Neurol Clin 1997, 15:615–648. This chapter provides a comprehensive review of the literature up to 1997 and also provides an extensive reference list for those interested in reviewing the multitude of case series of PM or DM that have been published in the English language literature.
Pachman LM: Juvenile dermatomyositis: pathophysiology and disease expression. Ped Rheumatol 1995, 42:1071–1098.
Sigurgeirsson B, Lindelof B, Edhag O, Allander E: Risk of cancer in patients with dermatomyositis or polymyositis: a population study. N Engl J Med 1992, 326:363–367.
Bohan A, Peter JB, Bowman RL, Pearson CM: A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977, 56:255–286.
Tymms KE, Webb J: Dermatomyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol 1985, 12:1140–1148.
Callen JP: Relationship of cancer to inflammatory muscle diseases: dermatomyositis, polymyositis, and inclusion body myositis. Rheum Dis Clin North Am 1994, 20:943–953.
Hill CL, Zhang Y, Sigurgeirsson B, et al.: Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001, 357:96–100.
Hochberg MC, Feldman D, Stevens MB: Adult-onset polymyositis/dermatomyositis: analysis of clinical and laboratory features and survival in 76 cases with a review of the literature. Semin Arthritis Rheum 1986, 15:168–178.
Love LA, Leff RL, Fraser DD, et al.: A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991, 70:360–374.
Targoff IN: Immune manifestations of inflammatory disease. Rheum Dis Clin North Am 1994, 20:857–880.
Dickey BF, Myers AR: Pulmonary disease in polymyositis/dermatomyositis. Semin Arthritis Rheum 1984, 14:60–76.
Greenberg SA, Sanoudou D, Haslett JN, et al.: Molecular profiles of the inflammatory myopathies. Neurology 2002, 59:1170–1182.
Mosaffar T, Pestronk A: Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighboring muscle fibers. J Neurol Neurosurg Psychiatry 2000, 68:472–478.
Miller T, Al-Lozi MT, Lopate G, Pestronk A: Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002, 73:420–428.
Streib EW, Wilbourn AJ, Mitsumoto H: Spontaneous electrical muscle fiber activity in polymyositis and dermatomyositis. Muscle Nerve 1979, 2:14–18.
Mitz M, Chang GJ, Albers JW, Sulaiman AR: Electromyographic and histologic paraspinal abnormalities in polymyositis/dermatomyositis. Arch Phys Med Rehabil 1981, 62:118–121.
Kissel JT, Mendell JR, Rammohan KW: Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986, 314:331–334.
Kissel JT, Halterman RK, Rammohan KW, Mendell JR: The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch Neurol 1991, 48:26–30.
De Visser M, Emslie-Smith AM, Engel AG: Early ultrastructural alterations in adult dermatomyositis: capillary abnormalities precede other structural changes in muscle. J Neurol Sci 1989, 94:181–192.
Bunch TW, Worthington JW, Combs JJ, et al.: Azathioprine with prednisone for polymyositis: a controlled, clinical trial. Ann Intern Med 1980, 92:365–369.
Bunch TW: Prednisone and azathioprine for polymyositis: long-term follow-up. Arthritis Rheum 1981, 24:45–48.
Dalakas MC, Illa I, Dambrosia JM, et al.: A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 1993, 329:1993–2000. Although from 1993, this is the only double-blind, placebocontrolled trial of any treatment for PM or DM to show benefit.
Cherin P, Pelletier S, Teixeira A, et al.: Results and longterm followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002, 46:467–474.
Al-Mayouf SM, Laxer RM, Schneider R, et al.: Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 2000, 27:2498–2503.
Wada J, Shintani N, Kikutani K, et al.: Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition. Clin Exp Immunol 2001, 124:282–289.
Miller FW, Leitman SF, Cronin ME, et al.: Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992, 326:1380–1384.
Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporine A in the treatment of refractory adult polymyositis/dermatomyositis: population-based experience in six patients and literature review. J Rheumatol 2000, 27:2855–2859.
Joffe MM, Love LA, Leff RL: Drug therapy of idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993, 94:379–387.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Briemberg, H.R., Amato, A.A. Dermatomyositis and polymyositis. Curr Treat Options Neurol 5, 349–356 (2003). https://doi.org/10.1007/s11940-003-0025-9
Issue Date:
DOI: https://doi.org/10.1007/s11940-003-0025-9